PMCID: PMC5462521 DOI: 10.1080/23723556.2017.1295127
The Hippo pathway is an important signaling pathway that controls cell proliferation and apoptosis. It is evolutionarily conserved in mammals and is stimulated by cell-cell contact, inhibiting cell proliferation in response to increased cell density. During early embryonic development, the Hippo signaling pathway regulates organ development and size, and its functions result in the coordinated balance between proliferation, apoptosis, and differentiation. Its principal effectors, YAP and TAZ, regulate signaling by the embryonic stem cells and determine cell fate and histogenesis. Dysfunction of this pathway contributes to cancer development in adults and children. Emerging studies have shed light on the upregulation of Hippo pathway members in several pediatric cancers and may offer prognostic information on rhabdomyosarcoma, osteosarcoma, Wilms tumor, neuroblastoma, medulloblastoma, and other brain gliomas. We review the results of such published studies and highlight the potential clinical application of this pathway in pediatric oncologic and pathologic studies. These studies support targeting this pathway as a novel treatment strategy.
Mol Cell Oncol
Neoplasms; Child; YAP1 (Yes-associated) protein, human [Supplementary Concept]; Hippo protein, human [Supplementary Concept]; Signal Transduction; Apoptosis; Cell Proliferation
Cancer; Hippo; YAP; pathways; pediatric
Ahmed, Atif; Mohamed, Abdalla D.; Gener, Melissa; Li, Weijie; and Taboada, Eugenio, "YAP and the Hippo pathway in pediatric cancer." (2017). Manuscripts, Articles, Book Chapters and Other Papers. 1130.